Standard Historical Financial Ratios
LAB Stock | USD 1.07 0.02 1.90% |
Standard Biotools is promptly reporting on over 102 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Stock Based Compensation To Revenue of 0.19 will help investors to properly organize and evaluate Standard Biotools financial condition quickly.
Standard |
About Standard Financial Ratios Analysis
Standard BiotoolsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Standard Biotools investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Standard financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Standard Biotools history.
Standard Biotools Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Standard Biotools stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Standard Biotools sales, a figure that is much harder to manipulate than other Standard Biotools multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Standard Biotools dividend as a percentage of Standard Biotools stock price. Standard Biotools dividend yield is a measure of Standard Biotools stock productivity, which can be interpreted as interest rate earned on an Standard Biotools investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Most ratios from Standard Biotools' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Standard Biotools current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.At present, Standard Biotools' Price To Sales Ratio is projected to drop slightly based on the last few years of reporting. The current year's Stock Based Compensation To Revenue is expected to grow to 0.19, whereas PTB Ratio is forecasted to decline to 0.92.
2021 | 2022 | 2025 (projected) | Current Ratio | 1.45 | 4.81 | 1.58 | Intangibles To Total Assets | 0.49 | 0.3 | 0.36 |
Standard Biotools fundamentals Correlations
Click cells to compare fundamentals
Standard Biotools Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Standard Biotools fundamentals Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Price To Sales Ratio | 3.13 | 2.28 | 0.94 | 1.65 | 3.54 | 4.32 | |
Ptb Ratio | 3.11 | 3.14 | (1.12) | 1.07 | 0.96 | 0.92 | |
Free Cash Flow Yield | (0.16) | (0.0651) | (0.19) | (1.02) | (0.26) | (0.25) | |
Operating Cash Flow Per Share | (0.21) | (0.58) | (1.14) | (0.55) | (0.41) | (0.43) | |
Capex To Depreciation | 0.8 | 0.85 | 0.25 | 0.19 | 1.92 | 0.97 | |
Pb Ratio | 3.11 | 3.14 | (1.12) | 1.07 | 0.96 | 0.92 | |
Free Cash Flow Per Share | (0.39) | (0.76) | (1.19) | (0.58) | (0.43) | (0.45) | |
Inventory Turnover | 2.78 | 2.94 | 2.84 | 2.72 | 2.45 | 2.01 | |
Net Income Per Share | (0.74) | (0.78) | (2.43) | (0.94) | (0.52) | (0.55) | |
Payables Turnover | 5.95 | 5.77 | 7.69 | 6.05 | 5.45 | 5.16 | |
Capex To Revenue | 0.003293 | 0.0216 | 0.0921 | 0.0266 | 0.0479 | 0.0844 | |
Pocfratio | (28.04) | (6.74) | (1.03) | (4.04) | (4.3) | (4.52) | |
Interest Coverage | (14.29) | (17.65) | (26.83) | (16.77) | (15.1) | (15.85) | |
Pfcf Ratio | (15.36) | (5.18) | (0.98) | (3.79) | (4.07) | (4.27) | |
Roe | (0.42) | (0.38) | (0.63) | 2.33 | (0.53) | (0.55) | |
Pe Ratio | (8.15) | (5.02) | (0.48) | (2.34) | (3.34) | (3.5) | |
Earnings Yield | (0.28) | (0.12) | (0.2) | (2.07) | (0.43) | (0.3) | |
Intangibles To Total Assets | 0.57 | 0.45 | 0.49 | 0.3 | 0.33 | 0.36 | |
Current Ratio | 2.93 | 2.17 | 1.45 | 4.81 | 1.66 | 1.58 | |
Receivables Turnover | 5.43 | 7.13 | 5.67 | 5.41 | 4.87 | 4.15 | |
Debt To Equity | 0.69 | 1.18 | (1.26) | 0.6 | 0.54 | 0.82 | |
Revenue Per Share | 1.92 | 1.72 | 1.25 | 1.34 | 0.49 | 0.47 | |
Debt To Assets | 0.29 | 0.41 | 0.26 | 0.3 | 0.35 | 0.5 | |
Days Sales Outstanding | 67.17 | 51.21 | 64.39 | 67.48 | 77.6 | 83.29 | |
Book Value Per Share | 1.93 | 1.25 | (1.04) | 2.06 | 1.86 | 1.95 | |
Ev To Sales | 3.32 | 2.91 | 1.15 | 2.08 | 2.39 | 4.6 | |
Days Of Inventory On Hand | 131.1 | 124.19 | 128.7 | 134.09 | 154.21 | 197.1 | |
Cash Per Share | 0.95 | 0.38 | 2.12 | 1.45 | 1.67 | 1.59 | |
Days Payables Outstanding | 61.39 | 63.22 | 47.43 | 60.32 | 69.37 | 88.13 | |
Ev To Operating Cash Flow | (29.78) | (8.63) | (1.26) | (5.12) | (4.6) | (4.83) | |
Ev To Free Cash Flow | (16.32) | (6.63) | (1.21) | (4.8) | (4.32) | (4.54) | |
Net Debt To E B I T D A | (0.78) | (1.9) | (0.12) | (0.85) | (0.98) | (1.03) | |
Tangible Book Value Per Share | (0.11) | (0.52) | (2.56) | 0.7 | 0.63 | 0.66 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Standard Biotools offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Standard Biotools' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Standard Biotools Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Standard Biotools Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share | Quarterly Revenue Growth (0.14) | Return On Assets | Return On Equity |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.